Immunological efficacy of a prime-boost strategy combining a 7-valent pneumococcal conjugate vaccine (PCV) [pneumococcal 7-valent CRM197 vaccine conjugate] followed by a 23-valent pneumococcal polysaccharide vaccine (PPV) [pneumococcal vaccine] versus PPV alone in HIV-infected adults. ANRS 114 PNEUMOVAC

Trial Profile

Immunological efficacy of a prime-boost strategy combining a 7-valent pneumococcal conjugate vaccine (PCV) [pneumococcal 7-valent CRM197 vaccine conjugate] followed by a 23-valent pneumococcal polysaccharide vaccine (PPV) [pneumococcal vaccine] versus PPV alone in HIV-infected adults. ANRS 114 PNEUMOVAC

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2008

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Mar 2008 Status changed from discontinued to completed according to clinicaltrials.gov.
    • 25 Feb 2007 Interim results have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top